San Diego, CA. (April 2nd, 2019). Reveal Biosciences, Inc., a leader in pathology AI, announces today that it has closed a Series A financing round led by Intel Capital with additional investment from the GNI
Reveal Biosciences attended Biocom’s recent CRO seminar on Pre-Clinical Efficacy Models for Immuno-Oncology Studies in Humanized Mice. Pharmatest Services and Taconic Biosciences hosted this informative seminar where they presented on humanized immune system models for
Reveal Biosciences Founder and CEO, Dr. Claire Weston, was recently featured in the Tech Spotlight interview series. This interview covered topics such as the inception of Reveal Biosciences, the future impact of AI on pathology,
Casey Laris, CTO of Reveal Biosciences, lead a webinar entitled “Revolutionize Pathology using Artificial Intelligence” as part of the Science Exchange Webinar Series. Highlights from this webinar include: Reveal Biosciences specializes in data powered pathology.
The hematoxylin and eosin (H&E) stain has long been an essential tool in the pathologist’s arsenal. Positively-charged hematoxylin and negatively-charged eosin bind to different substances within a tissue sample. This allows pathologists to clearly view